Physician Assistant Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Keifer Richardson

Physician Assistant, Medical Augusta, GA Physician Assistant

NPI 1174031660 CMS profile 4573637

2050 Walton Way, Augusta, GA 30904

Open in the dashboard

General payments

$14,256

560 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Keifer Richardson of Augusta, GA is reported in the CMS Open Payments database as having received $14,256 across 560 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,427 98
2024 General $3,288 81
2023 General $2,608 112
2022 General $3,607 128
2021 General $2,312 140
2020 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keifer Richardson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Keifer Richardson were reported at $2,427. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Keifer Richardson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $15 $20 $14–$64 $114
2021 $2,312 $156 $41–$563 $132
2022 $3,607 $185 $55–$649 $149
2023 $2,608 $199 $58–$717 $160
2024 $3,288 $206 $62–$740 $164
2025 $2,427 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Mannkind Corporation $2,169 46 payments
  2. Medtronic, Inc. $2,142 24 payments
  3. Novo Nordisk Inc $1,030 57 payments
  4. Corcept Therapeutics $981 33 payments
  5. Lilly USA, LLC $967 57 payments
  6. Xeris Pharmaceuticals, Inc. $878 38 payments
  7. Dexcom, Inc. $702 42 payments
  8. Amgen Inc. $690 44 payments
  9. Beta Bionics, Inc. $492 14 payments
  10. AstraZeneca Pharmaceuticals LP $483 27 payments
  11. Other $3,722 178 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $11,489 548 payments
  2. Travel and Lodging $2,061 7 payments
  3. Consulting Fee $597 1 payment
  4. Education $109 4 payments
Products named General payments · program years 2020–2025
  1. AFREZZA $2,169 46 payments
  2. MINIMED 780G $2,060 19 payments
  3. Korlym $981 33 payments
  4. Ozempic $805 48 payments
  5. RYBELSUS $693 40 payments
  6. Dexcom G6 Transmitter $580 33 payments
  7. FARXIGA $483 27 payments
  8. Omnipod $413 15 payments
  9. JARDIANCE $408 26 payments
  10. iLet Insulin Infusion Kit Inset $386 10 payments
  11. Other $8,555 418 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 99 drugs

Part D claims

9,554

Median for Physician Assistant: 241

Drug cost

$3,355,252

Median for Physician Assistant: $4,110

Branded share of claims

46.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 1,075 $1,186,583
Jardiance Empagliflozin Brand 487 $405,132
Farxiga Dapagliflozin Propanediol Brand 444 $367,852
Trulicity Dulaglutide Brand 245 $292,604
Mounjaro Tirzepatide Brand 181 $212,213
Januvia Sitagliptin Phosphate Brand 163 $120,998
Afrezza Insulin Regular, Human Brand 13 $73,284
Tresiba Flextouch U-100 Insulin Degludec Brand 100 $62,488
Tradjenta Linagliptin Brand 79 $52,186
Prolia Denosumab Brand 28 $48,543

The 10 drugs with the highest cost, of 99 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$159,755

Of which drugs: $807

Medicare patients

745

Average age 74

Services billed

4,391

463 women, 282 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 71%
Arthritis 46%
Chronic kidney disease 33%
Ischemic heart disease 29%
Osteoporosis 27%
Depression 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 18 18 $394
Injection, zoledronic acid, 1 mg J3489 Office 13 55 $299

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RECORLEV
  • Xeris Pharmaceuticals, Inc. $140
$140 — —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $128
$128 38 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $59
  • Lilly USA, LLC $42
$101 487 —
Korlym
  • Corcept Therapeutics $89
$89 — —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

560 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record